Abstract
The growth response of resident glomerular cells is determined by the underlying disease. Thus glomerular cells can proliferate, fail to proliferate, hypertrophy or apoptose. Cell growth is controlled by cell cycle regulatory proteins, and cell proliferation requires that cyclin-dependent kinases (CDK) be activated by partner cyclins. Inhibiting CDK2 reduces mesangial cell proliferation. Mesangial cell proliferation also requires that levels of specific cyclin kinase inhibitors (CKI) decrease. In contrast, the visceral glomerular epithelial cells’ inability to proliferate may be due to increased levels of CKI. Moreover it is becoming increasingly clear that mesangial cell hypertrophy in diabetes requires increased CKI expression. Finally, apoptosis, which is often linked to proliferation, may also be due to the increased activity of CDK2. Thus, identifying specific cell cycle regulatory proteins following injury may provide future targets for therapy in glomerular disease.
References
1.
Pardee AB: G1 events and regulation of cell proliferation. Science 1989;246:603–608.
2.
Sherr CJ: Mammalian G1 cyclins. Cell 1993;73:1059–1065.
3.
Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149–1163.
4.
Johnson RJ: The glomerular response to injury: Progression or resolution? Kidney Int 1994;45:1769–1782.
5.
Schoecklmann HO, Rupprecht HD, Zauner I, Sterzel RB: TGF-β1-induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-CDK2 activation and retinoblastoma protein phosphorylation. Kidney Int 1996;51:1228–1236.
6.
Shankland SJ, Pippin J, Flanagan M, Coats SR, Nangaku M, Gordon KL, Roberts JM, Couser WG, Johnson RJ: Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. Kidney Int 1997;51:1088–1099.
7.
Shankland SJ, Hugo C, Coats SR, Nangaku M, Pichler RH, Gordon KL, Pippin J, Roberts JM, Couser WG, Johnson RJ: Changes in cell cycle protein expression during experimental mesangial proliferative glomerulonephritis. Kidney Int 1996;50:1230–1239.
8.
Shankland SJ, Hamel PA, Scholey JW: Cyclin and cyclin-dependent kinase expression in the remnant glomerulus. J Am Soc Nephrol 1996;8:368–375.
9.
Pippin JW, Qu Q, Meijer L, Shankland SJ: Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 1997;100:2512–2520.
10.
Terada Y, Yamada T, Nakashima O, Tamamori M, Ito H, Sasaki S, Marumo F: Overexpression of cell cycle inhibitors (p16INK4 and p21Cip1) and cyclin D1 using adenovirus vectors regulates proliferation of rat mesangial cells. J Am Soc Nephrol 1997;8:51–60.
11.
Ophascharoensuk V, Fero ML, Hughes J, Roberts JM, Shankland SJ: The cyclin-kinase inhibitor p27Kip1 safeguards against inflammatory injury. Nat Med 1998;4:575–580.
12.
Preisig PA, Franch HA: Renal epithelial hyperplasia and hypertrophy. Semin Nephrol 1995;15:327–340.
13.
Kuan CJ, Al-Douahji M, Shankland SJ: The cyclin kinase inhibitor p21WAF1, CIP1 is increased in experimental diabetic nephropathy: Potential role in glomerular hypertrophy. J Am Soc Nephrol 1998;9:986–993.
14.
Shankland SJ, Hamel PA, Scholey JW: Cyclin and cyclin-dependent kinase expression in the glomeruli of normal, diabetic and renal-ablated rats. J Am Soc Nephrol 1994;5:701.
15.
Park SK, Kang MJ, Kim I, Terhune A, Koh GY: Temporal expression of cyclin-dependent kinase inhibitors during renal development and hypertrophic renal growth (abstract). J Am Soc Nephrol 1996;7:1663.
16.
Shankland SJ, Hamel PA, Scholey JW: Phosphorylation of retinoblastoma protein in glomeruli of normal, diabetic and renal-ablated rats (abstract). J Am Soc Nephrol 1994;5:701.
17.
Wolf G, Schroeder R, Ziyadeh FN, Thaiss F, Zahner G, Stahl RAK: High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells: Relationship to hypertrophy. Am J Physiol 1997;42:F348–F356.
18.
Wolf G, Schroeder R, Thaiss F, Ziyadeh FN, Helmchen U, Stahl RAK: Glomerular expression of p27Kip1 in diabetic db/db mouse: Role of hyperglycemia. Kidney Int 1998;53:869–879.
19.
Kriz W: Progressive renal failure – Inability of podocytes to replicate and the consequences for development of glomerulosclerosis. Nephrol Dial Transplant 1996;11:1738–1742.
20.
Shankland SJ, Floege J, Thomas SE, Nangaku M, Hugo C, Pippin J, Henne K, Hockenberry DM, Johnson RJ, Couser WG: Cyclin kinase inhibitors are increased during experimental membranous nephropathy: Potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int 1997;52:404–413.
21.
Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ: Altered cell differentiation and proliferation in mice lacking p57Kip2 indicates a role in Beckwith-Wiedermann syndrome. Nature 1997;387:151–158.
22.
Coombs HL, Shankland SJ, Setzer SV, Hudkins KL, Alpers CE: Expression of the cyclin kinase inhibitor, p27Kip1, in developing and mature human kidney. Kidney Int 1998;53:892–896.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
